Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sharon Stoll

Neurology New Haven, CT Doctor of Osteopathy

NPI 1114211174 CMS profile 1382563

20 York St, New Haven, CT 06510

Open in the dashboard

General payments

$822,228

967 records reported · program years 2019–2025

Research payments

$32,218

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sharon Stoll of New Haven, CT is reported in the CMS Open Payments database as having received $822,228 across 967 general payments and $32,218 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $110,491 187
2025 Research $3,083 4
2024 General $118,434 133
2024 Research $1,680 4
2023 General $92,746 107
2023 Research $24,448 1
2022 General $145,260 177
2021 General $91,927 79
2020 General $94,720 88
2020 Research $3,006 4
2019 General $168,650 196

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharon Stoll
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sharon Stoll were reported at $110,491. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sharon Stoll Neurology median Middle half National median
2019 $168,650 $474 $118–$2,177 $163
2020 $94,720 $367 $82–$2,309 $114
2021 $91,927 $438 $104–$2,547 $132
2022 $145,260 $442 $103–$2,388 $149
2023 $92,746 $464 $119–$2,312 $160
2024 $118,434 $468 $119–$2,323 $164
2025 $110,491 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $290,257 259 payments
  2. Genzyme Corporation $127,803 109 payments
  3. Alexion Pharmaceuticals, Inc. $99,097 98 payments
  4. EMD Serono, Inc. $83,173 92 payments
  5. Novartis Pharmaceuticals Corporation $45,716 116 payments
  6. TG Therapeutics, Inc. $38,540 37 payments
  7. Horizon Therapeutics plc $38,047 38 payments
  8. E.R. Squibb & Sons, L.L.C. $25,593 23 payments
  9. Genentech USA, Inc. $18,236 41 payments
  10. Sanofi US Services Inc. $16,212 1 payment
  11. Other $39,552 153 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $536,984 172 payments
  2. Consulting Fee $163,584 72 payments
  3. Travel and Lodging $73,690 174 payments
  4. Food and Beverage $26,498 537 payments
  5. Honoraria $21,207 5 payments
  6. Education $264 7 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $100,363 107 payments
  2. TECFIDERA $64,828 62 payments
  3. VUMERITY $60,077 38 payments
  4. Mavenclad $57,066 24 payments
  5. ULTOMIRIS $49,915 34 payments
  6. AUBAGIO Multiple Sclerosis $38,835 39 payments
  7. UPLIZNA $38,047 38 payments
  8. BRIUMVI $36,600 36 payments
  9. AUBAGIO Neurology $33,302 33 payments
  10. ZEPOSIA $28,822 69 payments
  11. Other $141,979 372 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $25,169 2 payments
  2. F. Hoffmann-La Roche AG $5,369 7 payments
  3. Genentech, Inc. $1,680 4 payments

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$3,698

Medicare's payments for the services billed

Medicare patients

14

Average age 71

Services billed

26

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Mavenclad
$19,677 — —
BRIUMVI
$17,093 — —
ULTOMIRIS
$15,837 — —
ZEPOSIA
$15,220 — —
VUMERITY
$4,976 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

980 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record